Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Simulations Plus, Inc. - Common Stock (NQ: SLP )

31.77 -0.07 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 197,322
Open 32.11
Bid (Size) 28.01 (1)
Ask (Size) 33.24 (1)
Prev. Close 31.84
Today's Range 31.37 - 32.64
52wk Range 24.00 - 51.22
Shares Outstanding 20,206,550
Dividend Yield 0.76%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
From Simulations Plus, Inc.
Via Business Wire

Performance

YTD
+13.83%
+13.83%
1 Month
-3.55%
-3.55%
3 Month
+1.44%
+1.44%
6 Month
-13.74%
-13.74%
1 Year
-23.90%
-23.90%

More News

Read More
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Q1 Earnings Assessment
Via Benzinga
What to Expect from Simulations Plus's Earnings
Via Benzinga
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Earnings Scheduled For January 7, 2025
Via Benzinga
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the BTIG Digital Health Forum
From Simulations Plus, Inc.
Via Business Wire
Breaking Down Simulations Plus: 2 Analysts Share Their Views
Via Benzinga
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Stephens Annual Investment Conference
From Simulations Plus, Inc.
Via Business Wire
Forecasting The Future: 4 Analyst Projections For Simulations Plus
Via Benzinga
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases DILIsym® X
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® Version 12
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Stock Drops 15% Despite EPS Beat
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.